The integrin v3 plays a central role in angiogenesis. In this study, we used antisense oligodeoxyribonucleotides ( ONs ) directed against the v subunit of v3 to inhibit integrin expression. Ten ON sequences, which were selected by systematic alignment of computer -predicted secondary structures of v mRNA, were transfected into human umbilical vein endothelial cells ( HUVECs ). Following stimulation by PMA, five antisense ONs significantly inhibited v mRNA and protein expression in activated HUVEC at a concentration of 0.05 M with complete prevention of PMA -induced v up -regulation by the most potent antisense ON. Inhibition of v expression was associated with significant inhibition of migration of HUVEC by 28% and had no effect on proliferation and apoptosis. Moreover, transfection of antisense ON inhibited the formation of tube -like structures of HUVEC in Matrigel by 44%. In a cell culture model of angiogenesis consisting of a co -culture of endothelial cells with fibroblasts, transfection of antisense ONs resulted in an inhibition of tube formation of 61%. In conclusion, v antisense ONs are potent inhibitors of angiogenesis in vitro. They might, therefore, be a therapeutic alternative to antagonists, which directly bind to v integrins, and might be useful for the treatment of malignant tumors and hematological malignancies.
A ngiogenesis plays a key role in several pathological conditions such as the growth of malignant tumors and metastases, chronic inflammatory diseases, diabetic retinopathy, or restenosis following angioplasty. 1 -3 Therefore, the inhibition of neoangiogenesis could be beneficial for the treatment of cancer and inflammation. Angiogenesis is a multistep process including proliferation, migration, and tube differentiation of endothelial cells, 4 and depends on an interaction among cells, extracellular matrix molecules, cytokines, and proteases. One of the central molecules in capillary formation is the integrin v3. 5, 6 It is the adhesion receptor on endothelial cells for several extracellular matrix proteins containing the Arg -Gly-Asp tripeptide motive such as vitronectin, fibronectin, laminin, or collagen. 7, 8 The integrin -mediated interaction of the endothelial cells with the extracellular matrix supports migration and sustains survival of vascular cells in angiogenic blood vessels. 9, 10 v3 is up -regulated on cytokine -activated endothelial and smooth muscle cells as well as on vascular cells within tumors, whereas it is minimally expressed on quiescent vasculature. 5, 10, 11 Thus, v3 is a suitable target molecule to inhibit angiogenesis.
A variety of specific v3 antagonists have been used in animals and humans. They consist of monoclonal antibodies, 10, 12, 13 peptides, 1,14 -17 and small molecules. 18, 19 These agents inhibited angiogenesis as well as tumor growth in mice and have already been used in clinical trials for the treatment of cancer. 8 Another method to inhibit adhesive interactions is to specifically down -regulate the adhesion molecules by antisense oligodeoxyribonucleotides (ONs). 20, 21 Antisense ONs against various target molecules have already successfully been used in clinical studies to treat cancer, inflammatory diseases, or retinitis caused by cytomegalovirus. 22 -26 In this study, we identified antisense ONs directed against the mRNA of the v chain of v3 by a computer-aided and semiempirical method. In an attempt to examine the influence of our antisense -based v inhibitors on different steps of angiogenesis, we found that antisense -mediated downregulation of v on activated endothelial cells resulted in reduction of cellular migration and inhibition of angiogenesis in vitro. Antisense ONs might, therefore, be a therapeutic alternative to antagonists that directly bind to v3.
Methods

Identification of favorable mRNA target structures for antisense ONs
A computer-aided prediction of RNA secondary structures was performed as described. 27 In brief, the computer program mfold 2.0, which is included in the Heidelberg Unix Sequence Analysis Resources, 28 was used to predict secondary structures of a set of subsequences of the v cDNA. 29 The computer-predicted secondary structures of overlapping target sequences were compared. Based on this computer analysis, favorable target structures for antisense ONs such as large loops, bulges, joints, and free ends were selected. Antisense ON sequences were designed by empirical selection criteria. 27 
ONs
Antisense ONs and control ONs were synthesized as phosphorothioates by a commercial supplier. The alignment of the sequences of the antisense and control ONs with sequences of the NCBI nucleotide databases was performed using BLASTN 2.1.3 program (National Center for Biotechnology Information, Bethesda, MD ). Control ONs showed no homology with any cDNA sequence from the database.
Cells
Human umbilical vein endothelial cells ( HUVECs ) were obtained from PromoCell (Heidelberg, Germany ) and were cultured, according to the manufacturer's instructions, in endothelial cell growth medium containing 2% fetal calf serum, 0.1 ng /mL epidermal growth factor, 1 g/mL hydrocortisone, 1 ng/ mL basic fibroblast growth factor, 0.4% bovine hypothalamic extract with heparin, 50 ng/ mL amphotericin B, and 50 g /mL gentamicin. Medium and supplements were obtained from PromoCell.
Transfection of HUVEC
Transfection of HUVEC was performed with modifications as described. 20 In brief, cells were grown to confluence between 60% and 80% in six -well culture plates and washed with prewarmed (378C ) serum -free medium Opti -MEM ( Life Technologies, Karlsruhe, Germany ). An amount of 500 L of Opti -MEM, containing 5 g /mL cationic lipid DOTMA /DOPE ( Lipofectin; Life Technologies ), was added to the cells followed by addition of 500 L of Opti -MEM containing the ON at a final concentration of 0.05 M. The cells were incubated for 4 hours at 378C. Subsequently, the medium was replaced by Medium 199 ( Life Technologies ) supplemented with 10% fetal calf serum and 2 mM L -glutamine. After further incubation for 4 hours at 378C, the medium was replaced again with Medium 199 containing the supplements and 200 ng/ mL PMA for stimulation of v expression. 30 For further analyses, HUVECs were removed from the culture plate by trypsinization for 5 minutes with 1 mL of trypsin /EDTA at 378C 40 hours after stimulation with PMA. This defined trypsinization procedure was used because we could show that following trypsinization for 5 minutes at 378C, the reduction of surface v expression was below 5% in comparison with cells harvested by a cell scraper.
Immunofluorescence staining and flow cytometry
A total of 1Â10 5 cells were washed with PBS and incubated with the FITC -conjugated v/ CD51 monoclonal antibody ( clone AMF7; Coulter /Immunotech, Krefeld, Germany ) or an isotype -identical control (Becton Dickinson, Heidelberg, Germany ) in 500 mL of PBS containing 1% bovine serum albumin at 48C for 30 minutes. Following antibody staining, cells were washed and suspended in PBS. The cells were analysed for v expression using a Becton Dickinson FACSCalibur. Data were analysed using the Becton Dickinson CELL QUEST software after gating on viable cells. The mean fluorescence intensity (MFI ) of v was calculated by the software and expressed in arbitrary units. For the calculation of the relative v expression level in ON -transfected cells, MFI of PMA -stimulated cells was set at 100% in each experiment.
Quantitative real -time RT -PCR
Total RNA was isolated from 1Â10 5 HUVEC using the Qiagen RNeasy Kit ( Qiagen, Hilden, Germany ) according to the manufacturer's instructions. The RNA was reversely transcribed as described. 31 For detection and quantification of the v mRNA level, the LightCycler technology (Roche Molecular Biochemicals, Mannheim, Germany ) was used. For quantification, 10-, 100 -, 1000 -, and 10,000 -fold dilutions of cDNA from HUVEC were made, the crossing points of the v and GAPDH PCR were assessed, and transferred to the RelQuant software ( Roche Molecular Biochemicals), which calculated standard curves for the v and GAPDH PCR, respectively. The RelQuant software permitted that these two standard curves could be used for all subsequent quantitative v RT-PCR if a sample from the 100-fold cDNA dilution from the above -described dilution series was included as calibrator in each real -time PCR analysis. Based on the standard curves and the data from the calibrator sample, the RelQuant software calculated the level of v mRNA as the v /GAPDH ratio. The v/ GAPDH ratio of the calibrator sample was set at 1. Each sample was analyzed in duplicate.
Proliferation assay
For the assessment of the proliferation rate of HUVEC, transfection and stimulation were performed in 96-well plates. The volume of the Lipofectin / ON solution was 200 L instead of 1000 L. Forty hours following PMA stimulation, proliferation was measured by bromo-desoxyuridine uptake using a commercial ELISA ( colorimetric cell proliferation ELISA BrdU; Roche Molecular Biochemicals ) according to the manufacturer's instructions.
Apoptosis assay
The apoptosis rate was measured using an Annexin V binding assay. Forty -eight hours following transfection and 40 hours following PMA stimulation, 1. 
Transmigration assay
Migration of HUVEC was examined using transwell polycarbonate membranes with a diameter of 24 mm and a pore size of 8 m (Costar, Bodenheim, Germany ). Before use, transwell membranes were coated with fibronectin by an overnight incubation with 10 ng /mL fibronectin (Sigma, Deissenhofen, Germany ) at 378C and a subsequent incubation with 1% bovine serum albumin in PBS for 30 minutes at 378C. For the migration assay, 500 L of Medium 199 was added to the lower chambers of the transwells. Transfected HUVEC were trypsinized 40 hours after PMA stimulation and washed once with PBS. A total of 3Â10 4 cells were resuspended in 500 L of Medium 199 and were added to the upper chamber. After further incubation for 38 hours at 378C, the number of cells adherent to the bottom of the lower chamber was counted using a microscope.
Endothelial cell tube formation assay
To measure endothelial cell tube formation, the Matrigel basement membrane matrix (Becton Dickinson ) was used. Matrigel is a soluble basement membrane preparation extracted from the Engelbreth -Holm -Swarm mouse sarcoma, a tumor rich in extracellular matrix proteins. It provides the substrates necessary for the study of angiogenesis. 33 Forty -eight -well plates were coated with 100 L of Matrigel for 45 minutes according to the manufacturer's instructions. Transfected HUVECs were trypsinized 40 hours following stimulation with PMA. A total of 2.5Â10 4 cells were resuspended in 500 L of Medium 199 supplemented with 10% fetal calf serum and 2 mM L -glutamine and added to the Matrigel -coated wells. After an incubation time of 16 hours at 378C, the formation of tube -like structures was examined microscopically. From each well, six different photographs were taken. For quantification, the number of closed circles formed by the tube -like structures was counted on six photographs per well.
In vitro angiogenesis assay
To evaluate the antiangiogenic potential of the antisense ON, a commercial angiogenesis assay ( Angiogenesis Kit; CellSystems, St. Katharinen, Germany ) was used. The assay involves the co -culture of HUVEC with human diploid fibroblasts of dermal origin, which produce the extracellular matrix proteins collagen 1, collagen IV, fibronectin, elastin, and laminin. 34 The addition of matrix proteins or further growth factors other than those present in endothelial growth medium is not necessary. The endothelial cells proliferate and migrate in a 24-well plate through the matrix to form a network of anastomosing tubules, which closely resembles the capillary bed found in the chorioallantoic membrane assay. Tubule formation was confirmed by confocal and electron microscopy as described before. 34 The assay was performed according to the manufacturer's instructions. In brief, 3 days after delivery of the culture plates from the supplier, the medium was replaced with test compoundcontaining medium. The replacement of the medium and the addition of the test compounds were repeated every third day. After 14 days, the endothelial cells were stained for von Willebrand's factor using indirect immunocytochemistry as described in the manufacturer's instructions. From each well, five photographs were taken. The total length of the tubules visible on five different photographs from one well was measured by tracing the paths of each tubule using a mapreading distance wheel (ADAC, Düsseldorf, Germany ).
As test compounds, the ONs as well as suramin -a known angiogenesis inhibitor 35 -were used. The ONs were either added without transfection reagent at a final concentration of 0.5 M, or together with the cationic lipid Lipofectin at a concentration of 0.035 or 0.05 M as described above. The final suramin concentration was 20 M.
Statistical analysis
Data were expressed as mean and the standard deviation was calculated. For quantification of the antisense effects and for calculation of statistical significance, antisense ON -treated cells were compared with control ON -treated cells. Statistical significance was determined using the t test for paired samples. A P value < .05 was considered to be statistically significant.
Results
Selection of v -directed antisense sequences
The efficacy of short -chain antisense ONs is dependent on their hybridization to the long -chain target mRNA. Because
Cancer Gene Therapy
Antisense-mediated inhibition of the v integrin R Kronenwett et al hybridization of antisense ONs is influenced by the local configuration of the complementary nucleotides of the target mRNA, a computer-aided approach was used to identify favorable secondary structures in the v mRNA. Based on the computer-supported analysis of the v mRNA, five different sequence stretches appeared to be favorable target regions for antisense ONs. They were located within the 3 0 untranslated region of the v mRNA around positions 3700, 3880 (Fig 1A ), 4050, 4180 ( Fig 1B ) , and 4800 according to Ref. [29 ] . Ten different 20 -mer antisense sequences directed against these five target regions were designed on the basis of empirical selection criteria. Interestingly, no favorable target regions could be identified within the coding sequence of v. As control ONs, two different reverse sense ONs of v -directed antisense sequences and two further ONs, which had no homology with the v mRNA, were used. The sequences of the ONs and their target positions are presented in Figure 1C .
Inhibition of v expression by selected antisense ONs
For evaluation of the efficacy of the selected antisense ONs, a cell culture model with PMA -stimulated HUVEC was ( Fig 2 ) . This result indicates a complete inhibition of PMA -induced upregulation of v using the antisense ON v3880. Four antisense ONs reduced the v expression levels significantly between 20% and 25% in comparison with control ON and between 35% and 40% compared to PMA stimulation alone. Five antisense sequences had no significant effect. Following transfection of the control ONs rs -v3880, rs -v4174, 1840B, and rs -1840B, no significant reduction of the v 
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Antisense-mediated inhibition of the v integrin R Kronenwett et al expression level was observed in comparison to the Lipofectin control. In the following experiments, only the most effective antisense ON v3880 and its control ON rs -v3880 were used.
The specificity of the antisense ON v3880 was also demonstrated on the mRNA level. Using real -time RT-PCR, the crossing points of the v-specific PCR curves were in mean at cycle 23 in v3880-transfected cell samples in comparison with cycle 21.8 in control ONtransfected cell samples, whereas the crossing points of the GAPDH -specific PCR curves were similar in all samples (Fig 3A ) . Calculation of the v /GAPDH quotients using the relative quantification software demonstrated that the PMA -induced up-regulation of the v mRNA could be abrogated completely following transfection of the antisense ON v3880 (Fig 3B ) . An inhibition of the RT-PCR by antisense ON seems to be unlikely because PCR primer was complementary to the 5 0 end of the translated region of the mRNA, whereas the antisense ON v3880 was directed against the 3 0 untranslated region.
Effects of down -regulation of v integrin expression on proliferation, apoptosis, and transmigration
To assess the influence of the inhibited v expression levels on the proliferation of HUVEC, the transfection experiments were performed in 96-well plates and the proliferation rates were measured by bromo -desoxyuridine uptake. Stimulation of HUVEC by PMA resulted in a 2-fold greater proliferation rate in comparison to unstimulated cells ( Fig 4A ) . Following antisense -mediated inhibition of the v up-regulation, only a nonsignificant reduction of the proliferation rate of 7% was found in comparison with control ON -transfected PMA -stimulated cells, suggesting that the PMA -induced proliferation of HUVEC is independent from the v expression level.
The effect of v expression on the apoptosis rate of HUVEC was examined by an Annexin V binding assay ( Fig 4B ) . Unstimulated and untransfected HUVECs had an apoptosis rate of 13%, whereas PMA stimulation was associated with a significantly lower apoptosis rate of 4.5%. When PMA -stimulated HUVECs were transfected by the antisense ON v3880, the apoptosis rate of 5.8% was similar to the apoptosis rate of 8.9% observed in control ON -transfected cells, suggesting that the reduction of the apoptosis rate by PMA is not related to up -regulation of v.
Migration of endothelial cells plays an important role during angiogenesis. Therefore, we examined the influence of antisense -mediated inhibition of v expression on the migratory capacity of endothelial cells. In case of nonstimulated HUVEC, out of 3Â10 4 input cells, only 100-143 cells migrated through the fibronectin-coated transwell membrane. On the other hand, the number of PMAstimulated HUVECs that migrated through the membrane varied between 164 and 263, indicating a stimulation of migration by PMA. Transfection of the antisense ON v3880 in PMA -stimulated HUVEC resulted in a signifi- 
Inhibition of angiogenesis in vitro
In order to evaluate antiangiogenic effects of v -directed antisense ON, we used two human in vitro models for angiogenesis. In the first assay, the ability to form tube -like structures in a layer of the extracellular matrix preparation Matrigel was examined. The cultivation of PMA -stimulated HUVEC in Matrigel resulted in a network of tube -like structures ( Fig 5B ) . Following transfection of v3880 in PMA -stimulated cells, a significant inhibition of tubule formation of 44% was found in comparison with control ON -transfected PMA -stimulated cells ( Figs 5 and 6 ). Thus, v3880 could completely abrogate the PMA -induced network formation of HUVEC in Matrigel.
To evaluate the antiangiogenic potential of the antisense ON under conditions that better resemble the in vivo conditions, a second cell culture angiogenesis model was used. Due to co -cultivation of HUVEC with human dermal fibroblasts, which produce extracellular matrix proteins, a network of endothelial cell -derived tubules resembling a capillary bed was generated without the addition of PMA or growth factors ( Fig 7A ) . In comparison with control ON -treated cells, transfection of the antisense ON v3880 resulted in a significant inhibition of tube formation of 54% at 0.035 M and of 61% at 0.05 M final ON concentration ( Figs 7 and 8 ) . The antisense ON was almost as efficacious as suramin, an antiangiogenic drug that reduced the tubule length by 75%. To mimic conditions of a systemic clinical application of ON, the effect of v-directed antisense ON was examined without the use of the transfection reagent Lipofectin. Because ON uptake in HUVEC is substantially reduced without cationic lipids, cells were treated with a 10 -fold greater concentration of naked ON. Following an incubation period of 2 weeks with v3880 at 0.5 M, a significant reduction of tube formation of 48% was observed, indicating the biological activity of the vdirected antisense ON without the use of transfection agents.
Discussion
In this study, we identified an v integrin -directed antisense ON that completely inhibited v mRNA and protein upregulation in stimulated endothelial cells and prevented capillary formation using two in vitro models of human angiogenesis.
Angiogenesis is a multifactorial process that depends on the stimulation of quiescent vascular cells by growth factors such as basic fibroblast growth factor or vascular endothelial growth factor, as well as on the interaction of the integrins v3 and v5 with one of their ligands. 6, 8, 9 Steps during formation of new blood vessels are up -regulation of integrins, proliferation and migration 
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Antisense-mediated inhibition of the v integrin R Kronenwett et al of endothelial cells, vascular tube formation, and anastomosis of newly formed capillaries. In an attempt to examine the influence of our antisense -based v inhibitors on each of these five steps of angiogenesis, we used different in vitro assays. PMA -induced up-regulation of v integrin on HUVEC could be significantly inhibited by 5 of 10 antisense ONs selected by analysis of folding patterns of the v mRNA. This indicates that the computer-based selection method as used in our study could increase the probability to identify antisense sequences with maximal efficacy because selection of antisense sequences by chance results only in one effective antisense ON for every eight sequences tested. 36 However, despite the increased probability for identification of effective antisense sequences by computerbased approaches, the examination of a panel of antisense sequences in cell culture is still necessary in antisense experiments.
The inhibition of PMA -induced up-regulation of v by the antisense ON had no significant effect on the proliferation rate of the endothelial cells. This suggests that the proliferation rate of HUVEC is independent from the v expression level and that the increased proliferation rate of stimulated cells is not related to an up -regulation of the v integrins. Our data indicate that inhibition of angiogenesis by v antagonists is apparently not directly mediated by an inhibition of proliferation. On the other hand, we found a significant suppression of migration of antisense -transfected HUVEC through fibronectin -coated transwell membranes. The number of transmigrated stimulated cells following antisense transfection was as low as the number of quiescent untreated HUVECs, indicating a complete inhibition of PMA -induced migration by the v -directed antisense ON.
Studies using v3 -directed antibodies or peptides showed that these antagonists selectively promoted programmed cell death of newly sprouting blood vessels. 10 Therefore, survival of endothelial cells during a critical period of the angiogenic process might depend on v3 expression, and the inhibition of angiogenesis by v3 inhibitors is mediated by an induction of vascular cell apoptosis. 5, 10 In our study, selective inhibition of v upregulation by the antisense ON v3880 did not change the apoptosis rate in comparison with untransfected PMAstimulated HUVEC. This suggests that a selective inhibition of the v subunit is not sufficient to induce apoptosis in PMA -stimulated HUVEC.
Antisense -mediated inhibition of vascular tube formation and anastomosis of newly formed tubules were examined by the Matrigel assay and by an in vitro angiogenesis assay. The inhibition of v expression and transmigration correlated with the prevention of PMA -induced formation of a network of tube -like structures in the Matrigel layer. Considering the results from the proliferation, transmigration, and apoptosis assays, the inhibition of tube formation is mediated by a reduction of the motility of HUVEC rather than by inhibition of proliferation or induction of programmed cell death.
In contrast to our data using an v-directed antisense molecule, down -regulation of v3 by a 3 subunitdirected antisense RNA did not influence tube formation of HUVEC in Matrigel. 37 This difference might be explained by the existence of two different pathways of angiogenesis. 6 Both pathways are related to the two integrins v3 and v5 as well as to an angiogenic stimulus by growth factors as v3 antagonists blocked basic fibroblast growth factorinduced angiogenesis, whereas v5 antagonists blocked vascular endothelial growth factor -induced angiogenesis. This finding was supported by mice lacking a functional 3 subunit, which did not show evidence for perturbation of vasculogenesis and angiogenesis. 38 The development of blood vessels seemed to be normal in those mice, suggesting that reduced v3 levels could be compensated by other v integrins as, e.g., the related v5. In contrast, v-deficient mice embryos had a lethal phenotype due to a perturbation of the blood vessel development in the brain. 8 Therefore, selectively targeting the v subunit by antisense ON might block all v -dependent angiogenic pathways.
To be closer to the in vivo conditions of angiogenesis, a cell culture model with a branching network of endothelial cell-derived tubules that resembled a capillary bed was used. In this assay, HUVECs were co -cultivated with fibroblasts producing extracellular matrix proteins and growth factors. No further stimulation of HUVEC by PMA or growth factors was necessary. In line with the data of the transmigration and Matrigel assays, an inhibition of formation of capillary -like structures of 61% was observed following transfection of the antisense ON v3880. The antisense -mediated inhibition was almost as strong as the 75% inhibition induced by the antiangiogenic drug suramin, which served as positive control. Incubation of the HUVEC / fibroblast layer with naked ON resulted in an inhibition of angiogenesis to a similar extent as cationic lipid -mediated transfection of ON for which a 10 -fold -lower ON concentration was necessary. Apparently, the v-directed antisense ON is also efficacious without cationic lipids even though a higher ON concentration must be used. This finding is of relevance for a potential clinical application of vdirected antisense ON as transfection reagents cannot be applied systemically.
Different types of v integrin antagonists are currently evaluated in clinical trials for the treatment of patients with advanced cancer. A humanized anti -v3 monoclonal antibody (Vitaxin ) has successfully completed phase I and II trials showing no significant toxicity and stable disease or even tumor reduction in some patients. 8, 39 An anti -v cyclic peptide (EMD -121974 ), which showed antiangiogenic efficacy in vitro as well as in animal models, is tested in a clinical phase II study at present. 8 Considering the results of these studies and the efficacy of the antisense ON v3880 in vitro, our antisense -based v inhibitor could also be used in a clinical setting. Several clinical studies have demonstrated the safety and, to some extent, the efficacy of different oncogene -directed antisense ONs in patients with malignant diseases. 24 -26 However, the advantage of the antisense -mediated inhibition of the v subunit in comparison to v3-specific antibodies or peptides is the specificity for all v integrins, which might result in an inhibition of all v -dependent angiogenic pathways and not only of the v3 -dependent ones. 6 This point might be relevant for the therapeutic outcome of v antagonists because for different tumors with their diverse biology and
Antisense-mediated inhibition of the v integrin R Kronenwett et al developmental stages, a considerable heterogeneity in the angiogenic response has to be expected. However, for clinical studies, one has to consider two important points. Firstly, in our in vitro angiogenesis assay, cells were exposed to antisense ON for 14 days. Therefore, systemic long -term administration of v antisense ON will likely be necessary to achieve antiangiogenic effects in vivo and to prevent a resumption of growth of residual tumor cells. Secondly, v is expressed on several normal tissues 4 and antisense -mediated down -regulation of v impaired osteoclast function and induced dysmorphogenesis of the kidney. 40, 41 Thus, side effects of v inhibitors could be possible.
In addition, v integrins are expressed by some invasive tumors such as metastatic melanoma, late -stage glioblastoma, or breast cancer, and are suggested to be crucial in tumor progression. 42 -47 In line with these data, an v3-specific monoclonal antibody could efficiently block human v3 -positive malignant melanoma in mouse xenografts, whereas the antibody did not affect v3 -negative tumors. 48 Moreover, v -directed antisense ONs were already used to down -regulate the integrin expression on immortalized and tumor cells such as transformed B lymphocytes, 49 intestinal carcinoma, 50 as well as breast cancer cells. 51 Antisense ONs specific for v integrins might therefore also be used to exert a direct antitumor effect.
In conclusion, antisense -mediated down -regulation of v on endothelial cells results in an inhibition of angiogenesis in vitro. Thus, v -directed antisense ONs are useful for functional studies of the role of v integrins in neovascularization. In addition, our results provide the basis for the development of antisense -based inhibitors of neoangiogenesis, which might be helpful for the treatment of malignant tumors and hematological malignancies.
